2 research outputs found

    EVALUATION OF ANTI-DIABETIC POTENTIAL OF IXORA PAVETTAIN STREPTOZOTOCIN INDUCED DIABETIC RATS

    Get PDF
    Objective: Evaluation of anti-diabetic potential ofIxorapavetta in streptozotocin induced diabetic ratsMethods: Diabetes was induced by thesingle dose of streptozotocin (65 mg/kg body weight i. p.) to female Wistarrats. Diabetic rats were stabilized for six day and from seventh day butenolic fraction of Ixorapavetta(BIP) was administered at a dose of 250 mg/kg, p. o. and 500 mg/kg for 3 weeks. Glibenclamide 10 mg/kg P. O. was used as a standard. The effects of BIP and standard drug on following parameters were recorded - body weight, blood glucose and various biochemical parameters like serum lipid profile eg. total cholesterol (TC) and triglyceride (TG), HDL-C, LDL-C and VLDL. At the end of the study oxidative stress markers like CAT, GSH, and lipid peroxidation were analyzed in the pancreases. Histopathological changes were studied in pancreases of representative animals of the each group.Results: Administration of butenolic fractionof Ixorapavetta(BIP) at a dose of 250 mg/kg, p. o. and 500 mg/kg, p. o did not show any significant change in blood glucose level of normoglycemic rats, whereas, oral glucose tolerance test depicted significant (P<0.001) reduction in blood glucose level at 30 to 60 min. In streptozotocininduced diabetic rats, BIP was found significantly beneficial in controlling elevated blood glucose level and serum lipid parameters. The findings were strengthening by improved antioxidant status in diabetic rats as well as protection towards pathological damage of pancreases. The results showed by 500 mg/kg of butenol fractionof Ixorapavettawere comparable with standard treatment of Glibenclamide 10 mg/kg.Conclusion: Butenolfractionof Ixorapavettapossessanti-diabetic action in streptozotocin induced diabetic rats.Â
    corecore